KEGG   DRUG: Quavonlimab
Entry
D12233                      Drug                                   
Name
Quavonlimab (USAN/INN)
Formula
C6386H9914N1704O2003S42
Exact mass
143865.4564
Mol weight
143953.9924
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DNWMNWVRQA PGKGLEWLAQ IRNKPYNYET
YYSASVKGRF TISRDDSKNS VYLQMNSLKT EDTGVYYCTA QFAYWGQGTL VTVSSASTKG
PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSRDELTKNQ
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV
FSCSVMHEAL HNHYTQKSLS LSPG
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRTSENIY GGLNWYQRKP GKSPKLLIYG ATNLASGVSS
RFSGSGSGTD YTLTISSLQP EDVATYYCQN VLRSPFTFGS GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H98, H142-H198, H218-L214, H224-H'224, H227-H'227, H259-H319, H365-H423, H'22-H'98, H'142-H'198, H'218-L'214, H'259-H'319, H'365-H'423, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-CTLA4 antibody
Comment
Monoclonal antibody
Treatment of advanced solid tumors
Target
CTLA4 (CD152) [HSA:1493] [KO:K06538]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12233  Quavonlimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D12233  Quavonlimab (USAN/INN)
Other DBs
CAS: 2254059-25-9
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system